Earnings calls

Neuland Labs. concall ledger

Every earnings call for NEULANDLAB — management tone, guidance, KPIs and promise tracking, quarter by quarter.

NEULANDLAB · 6 transcripts · Healthcare · latest Q4 FY26

Q4 FY26Published 12 May 2026Call held 12 May 2026

NEULANDLAB Q4 FY26 Earnings Call Transcript & Analysis

Revenue₹2,053.1 cr+37% YoYEBITDA₹319.4 crEBITDA Margin40.5%PAT₹212.5 crGross Margin62.1%

Revenue (FY26) ₹2,053 cr (+37% YoY); EBITDA (Q4 FY26) ₹319 cr; EBITDA Margin (Q4 FY26) 40.5%. Q4 FY26 Total Income of ₹788.7 crores, up 134.9% YoY.

Read full transcript & analysis

Q3 FY26Published 09 Feb 2026Call held 09 Feb 2026

NEULANDLAB Q3 FY26 Earnings Call Transcript & Analysis

EBITDA Margin19%EPS₹31.5Total Income₹447.8 cr+11% YoY

EBITDA Margin 19%; EPS ₹31.5; Total Income ₹448 cr (+11% YoY). Total Income stood at ₹447.8 crores, a growth of 11.4% YoY.

Read full transcript & analysis

Q2 FY26Published 07 Nov 2025Call held 07 Nov 2025

NEULANDLAB Q2 FY26 Earnings Call Transcript & Analysis

EBITDA₹156.9 crEBITDA Margin30.4%PAT₹96.5 cr+202% YoYGross Margin60.1%EPS₹75.18

EBITDA ₹157 cr; EBITDA Margin 30.4%; PAT ₹96 cr (+202% YoY). Total Income surged to ₹516 crores, a 63.7% YoY increase from ₹315 crores in Q2FY25.

Read full transcript & analysis

Q1 FY26Published 31 Jul 2025Call held 31 Jul 2025

NEULANDLAB Q1 FY26 Earnings Call Transcript & Analysis

EBITDA₹42.1 crEBITDA Margin14.4%PAT₹13.7 cr−86% YoYGross Margin55.3%EPS₹10.7

EBITDA ₹42 cr; EBITDA Margin 14.4%; PAT ₹14 cr (−86% YoY). Total Income was ₹300.6 crores, a sharp decrease of 32.4% YoY from ₹444 crores in Q1FY25.

Read full transcript & analysis

Q4 FY25Published 15 May 2025Call held 15 May 2025

NEULANDLAB Q4 FY25 Earnings Call Transcript & Analysis

EBITDA₹58.2 cr−48% YoYEBITDA Margin17.3%PAT₹27.7 cr−59% YoYEPS₹21.6Total Income₹335.8 cr−14% YoY

EBITDA (Q4) ₹58 cr (−48% YoY); EBITDA Margin (Q4) 17.3%; PAT (Q4) ₹28 cr (−59% YoY). Q4 FY25 total income stood at ₹335.8 crores, a decrease of 14% YoY from ₹390.4 crores.

Read full transcript & analysis

Q3 FY25Published 11 Feb 2025Call held 11 Feb 2025

NEULANDLAB Q3 FY25 Earnings Call Transcript & Analysis

Revenue₹1,161.5 cr−2% YoYEBITDA₹90.3 cr−26% YoYEBITDA Margin22.5%PAT₹101.4 cr+26% YoYGross Margin53.2%

Revenue (9M) ₹1,162 cr (−2% YoY); EBITDA (Q3, ex-exceptional) ₹90 cr (−26% YoY); EBITDA Margin (Q3, ex-exceptional) 22.5%. Q3 FY25 Total Income stood at ₹401.9 crores, a slight increase of 1.8% YoY.

Read full transcript & analysis